Veozah Vms denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Requires Prior Authorization for Veozah

Veozah (fezolinetant) is subject to prior authorization (PA) under most UnitedHealthcare plans. A PA-required denial means your prescription was dispensed or submitted without an approved authorization on file, or an authorization was requested but denied because the submitted clinical information did not satisfy UHC's coverage criteria. Prior authorization for Veozah typically requires documentation of the diagnosis, symptom severity, and prior treatment history.

## Why This Is Appealable (and How to Approach It)

If the PA was denied — rather than simply not yet filed — you have full appeal rights. PA denials for Veozah are most often overturned when the appeal supplements the original submission with more detailed severity documentation, a complete prior treatment history, and a prescriber letter that directly addresses each of UHC's coverage criteria. If the PA was never submitted, filing it prospectively (with complete documentation from the outset) is faster than appealing a denial.

## Federal Appeal Framework

• PA reconsideration / internal appeal (ACA/ERISA §503): File within the timeframe on your denial notice (typically 60–180 days). Submit all additional clinical documentation not included in the original PA request.
• Expedited review: If VMS symptoms are severe and significantly impairing function, or if there is a clinical urgency, request an expedited appeal — decision required within 72 hours.
• External review (ACA §2719): If the internal appeal fails, you have approximately four months from the final denial to request independent external review. External reviewers evaluate whether the denial was clinically justified, not simply whether your documentation matched UHC's checklist.

## Documentation to Gather

1. Diagnosis and indication confirmation: Clinical documentation of menopause and moderate-to-severe VMS — frequency of episodes, impact on sleep and daily function — using the ICD-10 code(s) that match the FDA-approved indication. 2. Symptom severity detail: Quantified description from office notes (not just the PA form) of how frequently and severely VMS affects the patient. A validated symptom scale referenced in the chart is helpful. 3. Prior treatment history: Dates, agents, doses (from chart), duration, and outcomes of prior VMS treatments. Include hormone therapy trials or a documented clinical reason HT was not appropriate (contraindication, patient history, risk factors). 4. Prescriber medical-necessity letter: Should confirm the diagnosis, detail symptom severity, explain why Veozah is the appropriate treatment, and directly address each criterion in UHC's current coverage policy for fezolinetant. Reference the FDA-approved prescribing label and the relevant professional society guideline (e.g., NAMS). 5. UHC PA criteria checklist: Obtain UHC's current prior-authorization criteria for Veozah (available from your plan or UHC's provider portal) and confirm every criterion is addressed in the submission.

## Criteria-Mapping Structure for Your PA / Appeal Submission

| UHC PA Criterion | Submitted Documentation | |---|---| | Menopause diagnosis confirmed | ICD-10 code; clinical/lab confirmation from chart | | VMS severity meets coverage threshold | Frequency and severity from office notes | | Prior treatment trial(s) documented | Dates, agents, outcomes — or documented contraindication to HT | | Prescriber attestation | Letter from treating clinician addressing each criterion | | On-label use confirmed | FDA indication language cited; prescribing label attached |

Submitting a complete, criterion-mapped PA request from the start — rather than a minimal form — dramatically reduces the likelihood of a denial and speeds the authorization process.